Board of Directors

J. Mikael Totterman, Chairman and CEO

Prior to iCardiac Technologies Mr. Totterman was the Chief Operating Officer of VirtualScopics Inc. (VSCP), a leading developer of image-based biomarkers for improving pharmaceutical development. During his tenure at VirtualScopics, he lead several of rounds of venture capital funding as well as striking strategic investment relationships with Pfizer, Inc. and GE Healthcare. Additionally, he was instrumental in developing VirtualScopics original business plan and overseeing the growth of the organization. Earlier in his career, Mr. Totterman also served as a principal at 3Com Ventures, a $250 million venture capital fund based in Santa Clara, CA as well as building 3Com’s Network of Global Strategic Alliances with companies including Philips, Siemens, AT&T and British Telecom. He has also held positions at Boston Consulting Group as well as Gemini Consulting. Mr. Totterman received his Bachelors Degree in Engineering from Stanford University where he was a David Starr Jordan Scholar and his Masters of Business Administration from the Amos Tuck School at Dartmouth College.

Alex Zapesochny, Esq., President & COO, Board of Directors

Mr. Zapesochny is an experienced technology executive and attorney. As General Counsel and Director of Business Development for Lenel Systems International, a developer and global supplier of high-end software, products and services for the security industry, Mr. Zapesochny was part of a small executive management team that guided the company to extraordinary growth. The company expanded to serving over 10,000 organizations throughout 75 countries, including security-conscious entities such as Microsoft, Cisco, all three New York City-area airports, the Department of Homeland Security and over sixty percent of all Fortune 100 companies. The company’s financial growth earned it 39th place on Inc. magazine’s ranking of the nation’s fastest-growing privately-held companies, and Lenel was acquired for $440 million by United Technologies Corporation (NYSE: UTX) in March 2005. Mr. Zapesochny remained with UTC after the acquisition and continued in his legal and business development roles within the Lenel Systems subsidiary. In private practice, Mr. Zapesochny has provided legal and business counsel to early-stage companies. Mr. Zapesochny’s other experience includes being a trial attorney during his tenure as a New York City prosecutor, a policy division staff member in the Washington headquarters of a presidential campaign, and Co-Founder and Executive Director of an award-winning non-profit that expands the national registry of potential bone marrow and blood stem cell donors. Mr. Zapesochny did his undergraduate work at Cornell University and his graduate work at American University and the University of Oxford.

David E. Williams

Mr. Williams is the co-founder of MedPharma Partners, a Boston-based health care strategy consulting firm, which serves clients in technology-enabled health care services, pharmaceuticals, biotech, medical devices, and medical software. Mr. Williams is an internationally recognized expert in the business of health care and is the author of the Health business blog. Before co-founding MedPharma Partners he worked for ten years in the health care practice of the Boston Consulting Group and as an independent consultant. He began his career at the LEK Partnership, where he was a strategy consultant and mergers and acquisitions advisor in a variety of industries. He holds a BA in Economics from Wesleyan University, where he was elected to Phi Beta Kappa, and an MBA from Harvard Business School, with First Year Honors. He has acted as an instructor in MIT’s graduate-level Dynamics of Biomedical Technologies course in the Biomedical Enterprise Program. Mr. Williams is Chairman of the Board of medical risk management company Advanced Practice Strategies and is a board member and head of the development committee of the Hearts and Noses Hospital Clown Troupe, which provides professionally trained volunteer clowns to children facing serious illnesses.

J. Montieth "Monty" Estes, Esq.

Mr. Estes is Managing Partner of the Rochester office of Jaeckle Fleischmann & Mugel LLP and Administrator of the Firm's Intellectual Property practice group. He is also a partner in the Firm's Business, Corporate, Intellectual Property and Emerging Company practice groups where he concentrates his practice on advising emerging technology companies, including high tech start-ups, on legal and business issues, including how to develop and protect their intellectual property assets and how to secure stages of funding. Prior to joining Jaeckle Fleischmann, Mr. Estes served for four years as Counsel with Boylan, Brown, Code, Vigdor & Wilson. He started his legal career in 1969 with the law firm of Harris Beach as an associate and then a partner. From 1980 upon leaving Harris Beach, to 2000 when he joined Boylan Brown, he gained extensive experience as an executive and director of a number of public and private companies as well as financial service firms. He has served as Vice-President and General Counsel for Fourth Dimension Systems Corp., a Naples, Florida based ultrasound and electromagnetic wave technology supplier to the telecommunications and radar industries; Chairman and Chief Executive Officer of Optical Imaging Systems, Inc., a flat panel display manufacturer in Troy, Michigan; and Chief Operating Officer of Scientific Calculations, Inc., a CAD/CAM systems developer and vendor for electronic circuit and integrated circuit designers until the company was sold to Harris Corporation. He also worked in Florida for both Manning & Napier and Equitable prior to returning to Rochester in 2000. Mr. Estes is a member of the Upstate Alliance for Innovation, which is a consortium consisting of the University of Rochester, Rochester Institute of Technology, the University of Buffalo, the City of Rochester and the City of Buffalo. He is also a member of the Board of Directors of the High Tech Business Council, the Advisory Board of the Science and Technology Law Center of the Albany Law School, the Advisory Board of the Smart Start Venture Forum, the Board of Directors of the Upstate Venture Association of New York (UVANY), and the Advisory Board of Universities of Upstate New York Venture Forum (UNYTECH), which is a collaborative effort among leading research institutions in the Upstate New York.

Anik Bose

Anik Bose is a seasoned executive with experience in both information technology and biotechnology businesses. He has headed the business development functions at communications technology companies such as 3Com as well as biotechnology focused companies such as Monsanto. In his business development roles he has managed a $250 million corporate venture fund, spearheaded dozens of venture capital investments and executed numerous spin out transactions as well as several large M&A transactions having over $1.4billion in value. For Monsanto, Mr. Bose developed and implemented global biotech growth strategies targeted towards achieving a significant return on Monsanto's $10 billion of acquisitions. On the communications technology side, Mr. Bose architected the launch of the fastest growing Asian networking company (H3C), which achieved annual revenues of over $700 million within 36 months of launch. Mr. Bose is currently a partner at Benhamou Global Ventures. BGV is an early stage venture fund that assists entrepreneurs in building a new generation of high technology companies. Most recently he advised and led 3Com's $885 million acquisition of its joint venture in China with Huawei. Earlier in his career, Mr. Bose served as a Partner in the High Technology Practice of Deloitte Management Consulting in San Francisco. Mr. Bose holds a MBA from Boston College and BA in Economics from the University of Delhi, India.

José J. Coronas

Mr. Coronas is a General Partner in Trillium Group, a Rochester based private equity and venture capital firm. He also serves as Fund Manager of the University Technology Seed Fund. Mr. Coronas is an experienced executive with strong ties to the health industry. Prior to joining Trillium, he was president of Johnson and Johnson Clinical Diagnostics; vice president and general manager of Kodak's Clinical Diagnostics Division; and president and CEO of Genencor International, a Kodak bio-technology spinoff. He earned a B.S. from the University of Miami and an M.B.A. from the Simon School of Business, University of Rochester. Mr. Coronas is on the Board of Directors at CPAC, Inc; ESL Federal Credit Union; OyaGen, Inc; CL!X, Inc., Rocket Broadband Networks, Inc., New Scale Technologies, Inc., Thermal Gradient, Inc., ASTER Wireless, Inc., and Verant Identification Systems Inc.. He also serves as a trustee of Monroe Community College Foundation, Hillside Children's Foundation and Junior Achievement of Rochester. He is currently the Chairman of the Board of Trustees of St. John Fisher College.

Timothy G. Cockshutt

Mr. Cockshutt is Managing Director of Advantage Capital Partners, which he joined in 1998. His responsibilities include assessing investment opportunities, evaluating and structuring transactions and managing existing portfolio relationships. Prior to joining Advantage Capital Partners, Mr. Cockshutt had 21 years of experience with institutional funds involved in venture capital, private equity, and microcap investing. Most recently, he was associated with Meridian Advisors, LTD, a private investment fund. Prior to that, he was with Ventex Management, a private equity firm that managed an SBIC, and Criterion Investments, a venture capital firm that managed three institutional partnerships. Before becoming involved with venture capital, Mr. Cockshutt was a mining exploration geologist for British Petroleum in Camden, South Carolina and a consulting geologist with Ernest K. Lehmann & Associates in Minneapolis, Minnesota. Mr. Cockshutt received a B.Sc. in Geology from Kings College, University of London and a B.A. in English and Philosophy from Amherst College. He also received an M.B.A. from Rice University, where he also served as an Adjunct Professor. Mr. Cockshutt sits on the boards of several Advantage Capital Partners portfolio companies.

Brian S. Model (Board Advisor)

Mr. Model is a Managing Director of Stonehenge Growth Capital and is responsible for the fund’s Growth Equity investment activities. Stonehenge currently has 9 active Growth Equity portfolio companies in New York. He has been with the firm since 2001. Mr. Model currently serves on the Board of Directors of eHealth Global Technologies, Lumetrics, Lorica Solutions, Knovel (observer), and iCardiac Technologies (observer) and previously served on the Board of Directors of PixFusion and Medidata Solutions (observer). Mr. Model is active in the regional venture investing community, serving on the Board of Directors of the Upstate Venture Association of New York (UVANY), and speaking at events sponsored by the Business Council of New York, YoungStartup Ventures, FundingPost, the Long Island Capital Alliance, the Silicon Alley Entrepreneurs Club and Columbia Business School. Mr. Model has served as a judge or Advisory Board Member for business plan competitions and venture financing events sponsored by the Council for Economic Growth, UNYTECH, Pre-Seed Workshop, SIIA (Software & Information Industry Association), NY Venture Summit, FundingPost, The Wharton School, and Columbia Business School. In addition, Mr. Model serves as co-chairman of the Columbia Business School Alumni Club of New York’s Ventures Committee and is a mentor for Columbia Business School’s Lang Fund. Prior to joining Stonehenge, Mr. Model spent 12 years in the retail industry as Founder of a men's sportswear e-tailer, Vice President and Merchandise Manager of an upscale multi-store apparel retailer in New Jersey and as a graduate of the Macy's Executive Training Program in San Francisco. Mr. Model received his undergraduate degree in Economics from Duke University and has an MBA with Honors from Columbia Business School.